Lv72
3590 积分 2022-12-19 加入
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
13天前
已完结
Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma
20天前
已完结
No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry
22天前
已完结
T-cell exhaustion in multiple myeloma
24天前
已完结
SOHO State of the Art Updates and Next Questions | Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance
24天前
已完结
Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers
24天前
已完结
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
1个月前
已完结
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
1个月前
已完结
Impact of autonomic dysfunction in light chain amyloidosis patient with nephrotic syndrome and cardiac involvement
1个月前
已完结
Current landscape of CD3 bispecific antibodies in hematologic malignancies
1个月前
已完结
皖公网安备34019202002308
